Opinion|Videos|July 29, 2024

Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

Video content above is prompted by the following:

  • How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance? 

  • In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?

Related to this article